Michael Burry’s best current stock choices in 2025

Michael Burry, better known to predict the 2008 housing market crash and figured in The Grand Courtcontinues to draw attention with its highly concentrated and contrary investment approach.

His fund, Scion Asset Management, is not known to occupy dozens of positions in all sectors. Instead, Burry focuses on a small number of bets with a strong conviction. In the second quarter of 2025, its portfolio owned only six shares with a total value of around 56.25 million dollars. The composition strongly emphasizes consumer and health care companies, highlighting its defensive trends and its desire to buy quality names under pressure. Here are the best choices of Michael Burry’s current stock in the second quarter of 2025, according to his 13F file:

1. Investment style of Michael Burry and T2 2025 portfolio.

The Burry portfolio on June 30, 2025 reflects its preference for concentration. Six positions constitute the entire fund and only two represent more than forty percent of its total value. This type of targeted investment is a characteristic of its strategy. While many managers distribute the risks over dozens of names, Burry doubles fewer companies where he sees a significant increase in risks.

This quarter, the portfolio mix Lecline for consumer goods and health care, two areas that often ensure resilience on uncertain markets. His desire to take important positions in companies that have recently fallen into disgrace show that he has not abandoned his contrary instincts.

2. Estee Lauder: Burry’s greatest position despite a garnish

Estee Lauder is the largest in Burry, which represents 21.55% of its fund, with 150,000 shares worth around 12.1 million dollars. He reduced this position by 25% during the quarter, which signals a partial profit but not a lack of conviction. The declared purchase price was $ 80.80 and the action had increased to $ 90.74 by the end of the reference period, marking a gain of more than 12%.

Estee Lauder’s actions have experienced large swings in the past year, ranging from $ 48.12 to $ 101.93. The company has worked on the consequences of a lower demand in China and disruptions focused on the pandemic, but its brand world force remains undeniable. Burry maintains it as a basic outfit while managing the exhibition after a strong rebound.

3. Lululemon: a bet against premium clothes

His second position is Lululemon, representing 21.12% of the portfolio. Burry bought 50,000 shares at a declared average price of $ 2,37.58, but the share was $ 203.62 on the date of deposit, down more than 14%. His 52 -week range went from $ 185.95 to $ 423.32, highlighting the volatility of the course of his action.

Lululemon has faced opposite winds as growth slowed down, and investors have wondered if high -end sportswear can maintain the same momentum as in recent years. For many managers, these concerns would be a reason to leave. For Burry, they seem to be a reason to buy. His decision suggests that he sees the strength of the long -term brand and international expansion opportunities that could survive pressures on short -term profits.

4. Bruker Corporation: Play in Scientific Instruments

Bruker Corporation represents 18.31% of the portfolio. Burry bought 250,000 shares at $ 41.20, but the price fell to $ 34.24 on the report date, leaving him a loss of paper of almost 17%. The 52 -week range of the action extends from $ 30.00 to $ 72.70, showing its volatility.

Bruker specializes in scientific instruments and laboratory technology, a sector that generally does not make the headlines but plays a crucial role in the progression of research and health care. Its decrease since the entry of Burry is in accordance with its entry into companies when the feeling of the market is low. The purchase is perfectly written in its strategy for recovering assets undervalued with long-term relevance.

5. REGENERON Pharmaceuticals: a biotechnology winner in the portfolio

Regeneron represents 14% of Burry’s participations and was one of its most successful recent purchases. It has 15,000 shares acquired at $ 525 each, the share climbing to $ 573.91 on the deposit date for a gain of more than 9%. Regeneron’s price fluctuated from $ 475.76 to up to $ 1,206.03 in the past year, reflecting the volatility of biotechnology and the solid position of the company in the industry.

The company is best known for developing treatments in ophthalmology, oncology and immunology. Regeneron continues to generate substantial income and has a solid pipeline, which may have attracted Burry to the stock. Unlike some of its other positions, it is firmly in positive territory, giving a boost to its portfolio of health care innovation.

6. Mercadolibre: the Amazon of Latin America

Mercadolibre, often described as the Amazon of Latin America, represents 13.94% of the portfolio. Burry has 3,000 shares purchased on average of $ 2,613.67. On the date of deposit, the action fell to $ 2,364.01, which represents a drop of almost 10%. Its 52 -week commercial range goes from $ 1,646 to $ 2,645.22.

Mercadolibre operates electronic payment and digital payment companies in Latin America, which gives it double exposure to two massive growth markets. While the stock has dropped since Burry bought it, its long -term history remains convincing. Its position in the online retail trade and the fintech makes it one of the most dominant companies in the region, and Burry’s investment suggests that it thinks that its future growth will prevail over current volatility.

7. Unitedhealth group: defensive force in health care

Unitedhealth Group completes the portfolio at 11.09%. Burry bought 20,000 shares on average by $ 311.95, and the share was negotiated at $ 308.49 at the time of the declaration, just slightly below its entry price. The fork of the year is between $ 234.60 and $ 621.24, highlighting both its potential and its sensitivity to broader movements in the health care sector.

As a biggest health insurer in the United States, UNITEDHEALTH provides a strong defensive anchor in the Burry portfolio. It generates coherent cash flows, benefits from the scale and operates in a regular demand sector. By combining United with Regeneron and Bruker, Burry has built a significant exposure to health care that balances growth and stability.

Conclusion: what Burry’s choices in 2025 reveal on his strategy

Michael Burry’s portfolio in mid-2025 shows how deliberate and contrary his investment style is. With only six actions constituting the entire fund, each post reflects the conviction and a careful selection.

Its two most important participations, Estee Lauder and Lululemon, are the names of consumers confronted with challenges but supported by world brands. Bruker and Mercadolibre add contrary elements in scientific instruments and Latin American growth markets. REGENERON offers an exposure to biotechnology innovation, while UNITEDHEALTH adds a defensive layer in American health care.

These choices show that Burry does not continue the latest market trend. Instead, it focuses on sectors with long -term value, even if they are faced with short -term opposite winds. His choices of 2025 highlight a balance between the possibilities of recovery and defensive stability while remaining faithful to the concentrated style and high condemnation which made him one of the most watched investors today.